Search Results - "Hou, Shihe"

Abstract 348: ABI-009 (nab-Sirolimus) improves tumor accumulation and antitumor activity over oral mTOR inhibitors by Hou, Shihe, Schmid, Anita, Desai, Neil

“…Abstract Background: mTOR pathway has been implicated in cell survival and proliferation and is an attractive target for cancer therapy. ABI-009…”
Get full text

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration by Chen, Nianhang, Brachmann, Carrie, Liu, Xiping, Pierce, Daniel W., Dey, Joyoti, Kerwin, William S., Li, Yan, Zhou, Simon, Hou, Shihe, Carleton, Michael, Klinghoffer, Richard A., Palmisano, Maria, Chopra, Rajesh

“…Purpose nab -paclitaxel demonstrates improved clinical efficacy compared with conventional Cremophor EL (CrEL)-paclitaxel in multiple tumor types. This study…”
Get full text

Abstract 3896: Distinct pharmacokinetics, tissue distribution and CNS penetration of ABI-009 ( nab -Sirolimus) by Hou, Shihe, Schmid, Anita, Desai, Neil

“…Abstract Background: Activation of the mTOR signaling pathway is frequently observed in multiple types of cancer. The poor solubility and low oral…”
Get full text

nab -Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors by Wagner, Andrew J, Ravi, Vinod, Riedel, Richard F, Ganjoo, Kristen, Van Tine, Brian A, Chugh, Rashmi, Cranmer, Lee, Gordon, Erlinda M, Hornick, Jason L, Du, Heng, Grigorian, Berta, Schmid, Anita N, Hou, Shihe, Harris, Katherine, Kwiatkowski, David J, Desai, Neil P, Dickson, Mark A

“…Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm,…”
Get full text

In Adenovirus Type 12 Tumorigenic Cells, Major Histocompatibility Complex Class I Transcription Shutoff Is Overcome by Induction of NF-κB and Relief of COUP-TFII Repression by Hou, Shihe, Guan, Hancheng, Ricciardi, Robert P.

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Abstract P138: nab -Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts by Hou, Shihe, Du, Heng, Schmid, Anita N., Kwiatkowski, David J., Desai, Neil P.

“…Abstract Background: TSC1, TSC2, and PTEN genes are tumor suppressors in the mTOR pathway and can be inactivated or deleted across many cancers (Kwiatkowski,…”
Get full text

Abstract 3856: Antitumor activity of ABI-009 ( nab -rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma by Hou, Shihe, Grigorian, Berta, Schmid, Anita, Desai, Neil

“…Abstract Background: mTOR pathway has been implicated in cell survival and proliferation and is an attractive target for cancer therapy. Loss of PTEN, a…”
Get full text

Abstract 6486: Correlation of nab -sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab -sirolimus in combination with KRAS inhibitors by Hou, Shihe, Nieva, Jorge, Zalath, Maria, Desai, Neil

“…Abstract Background: KRAS mutations are found in a variety of tumor types, including non-small cell lung cancer (NSCLC), where KRAS G12C mutation is present in…”
Get full text

Abstract 5484: Synergistic antitumor activity of nab -sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts by Hou, Shihe, Kwon, Andrew, Nieva, Jorge, Desai, Neil

“…Abstract KRAS is frequently mutated in non-small cell lung cancer (NSCLC) and other tumor types, with KRAS G12C mutation representing ~12% of patients with…”
Get full text

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer by Rajeshkumar, N V, Yabuuchi, Shinichi, Pai, Shweta G, Tong, Zeen, Hou, Shihe, Bateman, Scott, Pierce, Daniel W, Heise, Carla, Von Hoff, Daniel D, Maitra, Anirban, Hidalgo, Manuel

“…Background: Albumin-bound paclitaxel ( nab -paclitaxel, nab- PTX) plus gemcitabine (GEM) combination has demonstrated efficient antitumour activity and…”
Get full text

Abstract 7196: Evaluation of nab -sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines by Myint, Khine Nyein, Wallace, Sean, Hou, Shihe, Zalath, Maria, McMorran, Brian, Kwon, Andrew, Vivanco, Igor

“…Abstract Background: Endocrine therapy (ET) is the standard of care for hormone receptor positive (HR+) breast cancer (BC), but ET resistance develops in most…”
Get full text

Phase I results from a phase 1/2 multi-center study of nab -sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss by Sharma, Sunil, Chiorean, E. Gabriela, Alistar, Angela Tatiana, Braiteh, Fadi S., Matrana, Marc Ryan, Becerra, Carlos Roberto, Grigorian, Berta, Hou, Shihe, Schmid, Anita N., Desai, Neil

“…Abstract only e16050 Background: The PI3K/mTOR pathway overactivation and loss of PTEN occur in 20-40% of mCRC pts. A recent phase 1/2 study in mCRC pts showed…”
Get full text

PATIENTS WITH SEVERE PULMONARY ARTERIAL HYPERTENSION TREATED WITH ABI-009, NAB-SIROLIMUS, AN MTOR INHIBITOR: INTERIM RESULTS FROM A PHASE 1 CLINICAL TRIAL by Simon, Marc, Gomberg-Maitland, Mardi, Oudiz, Ronald, Machado, Roberto, Rischard, Franz, Elinoff, Jason, Grigorian, Berta, Schmid, Anita, Hou, Shihe, Desai, Neil, Gladwin, Mark

Get full text

A phase I/II multicenter study of ABI-009 ( nab -sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss by Sharma, Sunil, Becerra, Carlos Roberto, Matrana, Marc Ryan, Alistar, Angela Tatiana, Chiorean, E. Gabriela, Schmid, Anita Nagypal, Grigorian, Berta, Hou, Shihe, Desai, Neil

“…Abstract only TPS730 Background: Very few treatment options are available for pts with mCRC beside the standard of care (SOC), 5-FU based chemotherapy +…”
Get full text

RBTT-01. A PHASE 2 TRIAL WITH ABI-009 (NAB-SIROLIMUS) AS SINGLE-AGENT AND COMBINATIONS IN RECURRENT HIGH-GRADE GLIOMA (rHGG) AND IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM) by Kesari, Santosh, Juarez, Tiffany, Carrillo, Jose, Truong, Judy, Nguyen, Minhdan, Heng, Annie, Gill, Jaya, Nguyen, Hanh, Nomura, Natsuko, Grigorian, Berta, Hou, Shihe, Schmid, Anita, Desai, Neil

“…Abstract BACKGROUND The mTOR pathway is frequently activated in patients with GBM and is associated with reduced survival, making this pathway a promising…”
Get full text

Long-term follow-up for duration of response (DoR) after weekly nab -sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT by Wagner, Andrew J., Ravi, Vinod, Riedel, Richard F., Ganjoo, Kristen N., Van Tine, Brian Andrew, Chugh, Rashmi, Cranmer, Lee D., Gordon, Erlinda Maria, Hornick, Jason L., Kwiatkowski, David J., Du, Heng, Grigorian, Berta, Schmid, Anita N., Hou, Shihe, Harris, Katherine, Desai, Neil, Dickson, Mark Andrew

“…Abstract only 11516 Background: Malignant PEComa is a rare, aggressive sarcoma, with no approved medical treatment. Cytotoxic chemotherapies have limited…”
Get full text

ABI-009 ( nab -sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial by Wagner, Andrew J., Ravi, Vinod, Ganjoo, Kristen N., Van Tine, Brian Andrew, Riedel, Richard F., Chugh, Rashmi, Cranmer, Lee D., Gordon, Erlinda Maria, Hornick, Jason L., Kwiatkowski, David J., Du, Heng, Grigorian, Berta, Schmid, Anita N., Hou, Shihe, Harris, Katherine, Desai, Neil, Dickson, Mark Andrew

“…Abstract only 11005 Background: Malignant PEComa is a rare, aggressive sarcoma, with no approved treatment or prior clinical trials. Case reports suggest mTOR…”
Get full text

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors by Abu‐Khalaf, Maysa M., Baumgart, Megan A., Gettinger, Scott N., Doddamane, Indukala, Tuck, David P., Hou, Shihe, Chen, Nianhang, Sullivan, Catherine, Lezon‐Geyda, Kimberly, Zelterman, Daniel, Hatzis, Christos, Deshpande, Hari, Digiovanna, Michael P., Azodi, Masoud, Schwartz, Peter E., Harris, Lyndsay N.

“…BACKGROUND The optimal weekly oral dose of sirolimus and intravenous nanoparticle albumin–bound paclitaxel (nab‐paclitaxel) were evaluated. METHODS A phase 1b…”
Get full text

Phosphorylation of Serine 337 of NF-κB p50 Is Critical for DNA Binding by Hou, Shihe, Guan, Hancheng, Ricciardi, Robert P.

“…It has been demonstrated that phosphorylation of the p50 subunit of NF-κB is required for efficient DNA binding, yet the specific phospho-residues of p50 have…”
Get full text

Tumor Necrosis Factor-α Stimulates Focal Adhesion Kinase Activity Required for Mitogen-activated Kinase-associated Interleukin 6 Expression by Schlaepfer, David D., Hou, Shihe, Lim, Ssang-Taek, Tomar, Alok, Yu, Honggang, Lim, Yangmi, Hanson, Dan A., Uryu, Sean A., Molina, John, Mitra, Satyajit K.

“…Focal adhesion kinase (FAK) is a cytoplasmic protein-tyrosine kinase that promotes cell migration, survival, and gene expression. Here we show that FAK…”
Get full text